These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25556617)

  • 61. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
    Prado CM; Baracos VE; Xiao J; Birdsell L; Stuyckens K; Park YC; Parekh T; Sawyer MB
    Appl Physiol Nutr Metab; 2014 Jun; 39(6):693-8. PubMed ID: 24869973
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Trabectedin's contribution to the treatment of sarcomas.
    Blay JY
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
    Pignata S; Scambia G; Bologna A; Signoriello S; Vergote IB; Wagner U; Lorusso D; Murgia V; Sorio R; Ferrandina G; Sacco C; Cormio G; Breda E; Cinieri S; Natale D; Mangili G; Pisano C; Cecere SC; Di Napoli M; Salutari V; Raspagliesi F; Arenare L; Bergamini A; Bryce J; Daniele G; Piccirillo MC; Gallo C; Perrone F
    J Clin Oncol; 2017 Oct; 35(29):3347-3353. PubMed ID: 28825853
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.
    Ferrandina G; Salutari V; Vincenzi B; Marinaccio M; Naglieri E; Loizzi V; Carpano S; Amadio G; Tonini G; Scambia G; Lorusso D
    Gynecol Oncol; 2013 Sep; 130(3):505-10. PubMed ID: 23774301
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
    Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
    Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Trabectedin and ovarian cancer (continued).
    Prescrire Int; 2011 Oct; 20(120):249-50. PubMed ID: 21970099
    [No Abstract]   [Full Text] [Related]  

  • 67. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
    Leporini C; Patanè M; Saullo F; Rende P; Gallelli L; Di Paola ED; Toscano R; Lucia M; Rossi M; De Sarro G; Russo E
    BioDrugs; 2014 Dec; 28(6):499-511. PubMed ID: 25209722
    [TBL] [Abstract][Full Text] [Related]  

  • 68. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
    Colombo N; Gadducci A; Sehouli J; Rulli E; Mäenpää J; Sessa C; Montes A; Ottevanger NB; Berger R; Vergote I; D'Incalci M; Churruca Galaz C; Chekerov R; Nyvang GB; Riniker S; Herbertson R; Fossati R; Barretina-Ginesta MP; Deryal M; Mirza MR; Biagioli E; Iglesias M; Funari G; Romeo M; Tasca G; Pardo B; Tognon G; Rubio-Pérez MJ; DeCensi A; De Giorgi U; Zola P; Benedetti Panici P; Aglietta M; Arcangeli V; Zamagni C; Bologna A; Westermann A; Heinzelmann-Schwarz V; Tsibulak I; Wimberger P; Poveda A;
    Br J Cancer; 2023 Apr; 128(8):1503-1513. PubMed ID: 36759720
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
    Poveda A; Kaye SB; McCormack R; Wang S; Parekh T; Ricci D; Lebedinsky CA; Tercero JC; Zintl P; Monk BJ
    Gynecol Oncol; 2011 Sep; 122(3):567-72. PubMed ID: 21664658
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
    Galizia D; Palesandro E; Nuzzo AM; Pignochino Y; Aliberti S; Aglietta M; Grignani G
    Oncol Res; 2013; 20(10):483-90. PubMed ID: 24308159
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Monk BJ; Brady MF; Aghajanian C; Lankes HA; Rizack T; Leach J; Fowler JM; Higgins R; Hanjani P; Morgan M; Edwards R; Bradley W; Kolevska T; Foukas P; Swisher EM; Anderson KS; Gottardo R; Bryan JK; Newkirk M; Manjarrez KL; Mannel RS; Hershberg RM; Coukos G
    Ann Oncol; 2017 May; 28(5):996-1004. PubMed ID: 28453702
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trabectedin has promising antineoplastic activity in high-grade meningioma.
    Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
    Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Trabectedin mechanism of action: what's new?
    D'Incalci M
    Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
    Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
    J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Introduction. Trabectedin treatment in GYN cancers.
    Poveda A
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S1-2. PubMed ID: 21540665
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.
    González Martín A
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S6-8. PubMed ID: 21540668
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
    Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M
    Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.